AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7114936
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy
Trial: 16531708
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant therapy
Trial: 30504515
Drug: Nitroglycerin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (200 μg or 300 μg)
Trial: 3935343
Drug: Verapamil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (5 mg)
Trial: 25458886
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psyllium and MgSO4 (n=12)
Trial: 18786302
Drug: Clopidogrel (600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600-mg loading dose, 75-mg maintenance dose for 7 days) with ranitidine (150 mg twice daily)
Trial: 11942372
Drug: Gadobenate dimeglumine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections of 0.05, 0.05 and 0.1 mmol/kg over a 20-min period
Trial: 11942372
Drug: Gadobenate dimeglumine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections
Trial: 19577405
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment sessions (control)
Trial: 18450989
Drug: 0.9 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g/kg dietary protein intake
Trial: 18450989
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg dietary protein intake
Trial: 30324849
Drug: Combination oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oxycodone (5‐mg) and acetaminophen (325‐mg) tablets
Trial: 25642582
Drug: Behavioral couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couples therapy (BCT-S)
Trial: 18837602
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation treatment (ST)
Trial: 25642582
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (BCT-S and ST)
Trial: 25063191
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ) treatment
Trial: 18360068
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (5 mg/day of enalapril or imidapril)
Trial: 15976965
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP)
Trial: 15976965
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP) in patients with Killip class III or IV
Trial: 12593493
Drug: Policosanol 10
RxNorm normalized name: policosanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 10 mg once daily
Trial: 8752186
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg once daily
Trial: 2063598
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 200 mg trapidil daily for 6 weeks
Trial: 2063598
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 200 mg pentoxifylline daily for 6 weeks
Trial: 28078862
Drug: Proprietary multi‐ingredient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary multi‐ingredient lipid‐lowering supplement (PMILLS)
Trial: 23417235
Drug: Booster intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster intervention (brief monthly individual contacts primarily with the children)
Trial: 2854781
Drug: Adjuvant intraluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intraluminal 5-FU chemotherapy and intravenous 5-FU chemotherapy (30 mg/kg intraluminally and 10 mg/kg intravenously on the first and second days postoperatively)
Trial: 2854781
Drug: Adjuvant intraluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intraluminal 5-FU chemotherapy
Trial: 30299412
Drug: Sucrose (SUC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (SUC; 40 g)
Trial: 30299412
Drug: Sodium nitrate
RxNorm normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium nitrate (NIT; 800 mg NO3)
Trial: 21911051
Drug: Bu‐Fei Yi‐Shen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bu‐Fei Yi‐Shen granule combined with Shu‐Fei Tie acupoint sticking therapy
Trial: 21911051
Drug: Oral sustained‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained‐release theophylline and placebo Bu‐Fei Yi‐Shen granule combined with placebo Shu‐Fei Tie acupoint sticking therapy
Trial: 15370670
Drug: DTPa-HBV-IPV/Hib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV/Hib combined vaccine (Group 1)
Trial: 9743769
Drug: Portfolio learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portfolio learning intervention where students followed a patient with cancer for 9 months, supported by bi-monthly small-group tutorials.
Trial: 22027699
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Zx plus 9 mg L
Trial: 22027699
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Zx, Zx + L, and L)
Trial: 9188761
Drug: Acute hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hyperglycemia (15 mmol/l)
Trial: 2689396
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m2
Trial: 2689396
Drug: Cisplatin 20
RxNorm normalized name: CISPLATIN 200MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 20 mg/m2
Trial: 16042882
Drug: famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famciclovir 500 mg tid
Trial: 9841843
Drug: Hib conjugates
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugates administered to young children (two or three primary doses)
Trial: 9841843
Drug: Three primary
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three primary vaccine doses
Trial: 2138180
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin plus zinc
Trial: 21360715
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg alone
Trial: 7997384
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg alone
Trial: 15252707
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine oestrogens plus 2.5 mg medroxyprogesterone acetate
Trial: 15790946
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate therapy
Trial: 8495532
Drug: Soya milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya milk preparations
Trial: 16989497
Drug: Felodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5-10 mg)
Trial: 2573003
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg Madopar
Trial: 21751250
Drug: Duloxetine 60/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60/120 mg per day for 12 weeks
Trial: 9395150
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment
Trial: 9370180
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group patients with less decrements of serum aluminum (<5.5 microg/L)
Trial: 3570859
Drug: Four types
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four types of milk with normal or low lactose and/or fat content, increasing amounts (125, 250, 500, 1000 ml/d)
Trial: 3570859
Drug: Increasing amounts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing amounts of milk (125, 250, 500, 1000 ml/d)
Trial: 21431329
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of 200 mg mifepristone orally and 400 μg misoprostol vaginally
Trial: 21431329
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 200 mg mifepristone orally and 400 μg misoprostol vaginally at 24-h interval
Trial: 21431329
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of 200 mg mifepristone and 400 μg misoprostol
Trial: 21431329
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 200 mg mifepristone and 400 μg misoprostol at 24-h interval
Trial: 27037432
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Trial: 27037432
Drug: Non-ultrasound guided
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Trial: 25158081
Drug: NRT patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT patches (15 mg per 16 hours) for 8 weeks
Trial: 20346057
Drug: Dextromethorphan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (30 or 45 mg)
Trial: 19015469
Drug: Alvimopan, 12
RxNorm normalized name: Alvimopan, 12 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan, 12 mg, administered orally 30 to 90 minutes preoperatively and twice daily postoperatively
Trial: 12444212
Drug: Chlorthalidone and
RxNorm normalized name: Chlorthalidone and clonidine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone and Amiloride combination
Trial: 9660361
Drug: Sequential initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential initiation of zidovudine and lamivudine
Trial: 9660361
Drug: Sequential initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential initiation of indinavir
Trial: 8620678
Drug: Zileuton 800mg
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton 800mg administered twice daily from day 4 to day 8
Trial: 8620678
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily from day 4 to day 8
Trial: 779756
Drug: Marijuana smoking
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana smoking (0.739 g)
Trial: 779756
Drug: Placebo smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo smoking (0.739 g)
Trial: 23647307
Drug: IWT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IWT plus post-exercise macronutrient supplementation (7.6 g protein, 32.5 g carbohydrate, and 4.4 g fat)
Trial: 17097995
Drug: Two bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two bolus doses of daclizumab (1 mg/kg) on days 1 and 14 posttransplantation
Trial: 17097995
Drug: Five bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five bolus doses of daclizumab (1 mg/kg) every 14 days
Trial: 17097995
Drug: Two bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two bolus doses of daclizumab
Trial: 65273
Drug: 0.7 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg delta9‐tetrahydrocannabinol (THC)
Trial: 65273
Drug: 1.0 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml/kg 95% ethanol
Trial: 24385118
Drug: Topical cosmetic
RxNorm normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cosmetic formulation containing N-acetyl tyrosinamide
Trial: 20708904
Drug: Intramuscular levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular levetiracetam (500mg, 5ml)
Trial: 20708904
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam
Trial: 18368612
Drug: Agonist pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agonist pharmacotherapy (specific agonists not detailed)
Trial: 12577189
Drug: Pamidronate 30
RxNorm normalized name: pamidronate 30 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 30 mg intravenously every 3 months, combined with 1000 mg calcium and 1000 IU vitamin D per day.
Trial: 12577189
Drug: Pamidronate treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate treatment.
Trial: 2200894
Drug: 1988-1989 trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1988-1989 trivalent split-antigen influenza vaccine
Trial: 23306361
Drug: Three injection
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injection techniques
Trial: 7970440
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at 140 micrograms kg‐1 min‐1
Trial: 7970440
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion combined with low-level dynamic exercise
Trial: 26903399
Drug: 1.0 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/day of oral 17β estradiol (E2) for 3 months
Trial: 26903399
Drug: 50 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg/day of transdermal 17βE2 for 3 months
Trial: 21211205
Drug: Single intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular 25 mg etanercept injection
Trial: 21211205
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml compound betamethasone
Trial: 14974908
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestradiol and 0.5 mg norethisterone
Trial: 1601148
Drug: hCG administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administered 1 day after criteria (Group 2, n = 84)
Trial: 31201809
Drug: Sacrospinous ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacrospinous ligament suspension
Trial: 25016216
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care treatment model for depression
Trial: 11231366
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin containing 1 mg of folic acid for four weeks
Trial: 2656096
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g iv for three doses/8 h)
Trial: 26850798
Drug: Teucrium polium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teucrium polium (250 mg q6h for the first 3 days of menstruation for two cycles)
Trial: 25656524
Drug: 25-hydroxycholecalciferol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxycholecalciferol (3 mg of Hidroferol, 180,000 IU)
Trial: 18480689
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg/d (2 x 10 mg)
Trial: 15837245
Drug: TAXUS stent
RxNorm normalized name: Taxus baccata fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAXUS stent (insulin-requiring subgroup)
Trial: 8522681
Drug: Cilazapril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (angiotensin-converting enzyme inhibitor)
Trial: 1884962
Drug: Hourly intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly intravenous injections of 100 mg of cimetidine along with a continuous nasogastric infusion of a liquid antacid at the rate of 0.5 ml per minute
Trial: 23602205
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg elemental Zn/day)
Trial: 11063377
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with autologous stem cell transplantation
Trial: 24894084
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT)
Trial: 19327952
Drug: Sequential Compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Compression Devices (SCDs)
Trial: 12891533
Drug: Daily lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lysine acetylsalicylate (aspirin) 160 or 300 mg/day
Trial: 8678279
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg mepivacaine without epinephrine
Trial: 26400955
Drug: Neuromuscular training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular training (NMT) group performing an injury prevention programme as a warm-up 3 times weekly for 12 weeks
Trial: 17668348
Drug: Cocaine injection
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine injection (0.5 mg/kg)
Trial: 10192753
Drug: PPS i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPS i.v. (50 mg)
Trial: 31620939
Drug: Lactobacillus reuteri-containing
RxNorm normalized name: Lactobacillus reuteri-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri-containing lozenges (2 lozenges/day after brushing for 3 months with a 3-month washout)
Trial: 23971720
Drug: Berberis aristata/Silybum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day after washout
Trial: 16179098
Drug: Carboplatin/vinorelbine every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/vinorelbine every 4 weeks as first-line treatment
Trial: 6510544
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin injections
Trial: 21246848
Drug: Nobex (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nobex (intramuscular injection)
Trial: 18261664
Drug: Hylan injections
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan injections
Trial: 15722306
Drug: Sub‐Tenon's block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub‐Tenon's block (STB) with 3 ml of 2% lidocaine and hyaluronidase
Trial: 15722306
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia (TOP) with proxymetacaine 0.5% and amethocaine 1% eye drops
Trial: 12651660
Drug: Anesthetic Conserving
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic Conserving Device (ACD) at 8 L/min FGF
Trial: 12651660
Drug: Circle system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circle system with 1‐, 1.5‐, 3‐, and 6‐L/min FGFs
Trial: 12651660
Drug: Low‐flow circle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐flow circle system (1.5‐ and 1‐L/min FGFs)
Trial: 9215287
Drug: tiratricol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiratricol (24 micrograms/kg twice daily)
Trial: 19747069
Drug: Oxybutynin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin IR 10 mg
Trial: 11110737
Drug: Galantamine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (24 mg)
Trial: 11110737
Drug: Galantamine (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (32 mg)
Trial: 9308074
Drug: Clonidine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (maximum daily dose 0.600 mg)
Trial: 9308074
Drug: Mianserin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (maximum daily dose 90 mg) and Carbamazepine (maximum daily dose 400 mg)
Trial: 8334029
Drug: 24,25-dihydroxy vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24,25-dihydroxy vitamin D3 (24,25(OH)2D3) (daily dose of 15 micrograms)
Trial: 8334029
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1,25(OH)2D3 and 24,25(OH)2D3